Insider Trading Alert - ALNY, SCX And NSIT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 27, 2015, 94 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $312.37 to $25,006,808.00.

Highlighted Stocks Traded by Insiders:

Alnylam Pharmaceuticals (ALNY) - FREE Research Report

Fanucci Marsha, who is Director at Alnylam Pharmaceuticals, sold 10,000 shares at $105.80 on Feb. 27, 2015. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 10,000-share transaction.

The shares most recently traded at $103.82, down $1.98, or 1.9% since the insider transaction. Historical insider transactions for Alnylam Pharmaceuticals go as follows:

  • 4-Week # shares bought: 11,000
  • 4-Week # shares sold: 10,200
  • 12-Week # shares bought: 11,000
  • 12-Week # shares sold: 11,737
  • 24-Week # shares bought: 11,000
  • 24-Week # shares sold: 11,737

The average volume for Alnylam Pharmaceuticals has been 716,500 shares per day over the past 30 days. Alnylam Pharmaceuticals has a market cap of $8.7 billion and is part of the health care sector and drugs industry. Shares are up 4.67% year-to-date as of the close of trading on Friday.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Currently, there are 5 analysts who rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALNY - FREE

TheStreet Quant Ratings rates Alnylam Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full Alnylam Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

L S Starrett (SCX) - FREE Research Report

Starrett Douglas A, who is President/CFO at L S Starrett, bought 1,000 shares at $17.36 on Feb. 27, 2015. Following this transaction, the President/CFO owned 10,109 shares meaning that the stake was boosted by 10.98% with the 1,000-share transaction.

Walsh Stephen F, who is Sr VP of Operations at L S Starrett, bought 500 shares at $17.36 on Feb. 27, 2015. Following this transaction, the Sr VP of Operations owned 1,000 shares meaning that the stake was boosted by 100% with the 500-share transaction.

Aspin Anthony M, who is VP in charge of Sales at L S Starrett, bought 333 shares at $17.36 on Feb. 27, 2015. Following this transaction, the VP in charge of Sales owned 666 shares meaning that the stake was boosted by 100% with the 333-share transaction.

Kennedy Richard, who is Director at L S Starrett, bought 100 shares at $17.36 on Feb. 27, 2015. Following this transaction, the Director owned 325 shares meaning that the stake was boosted by 44.44% with the 100-share transaction.

Lawrence Ralph C, who is Director at L S Starrett, bought 600 shares at $11.29 on Feb. 27, 2015. Following this transaction, the Director owned 1,900 shares meaning that the stake was boosted by 46.15% with the 600-share transaction.

Piper Terry A, who is Director at L S Starrett, bought 100 shares at $17.36 on Feb. 27, 2015. Following this transaction, the Director owned 400 shares meaning that the stake was boosted by 33.33% with the 100-share transaction.

O'Brien Francis J, who is Treasure & CFO at L S Starrett, bought 500 shares at $17.36 on Feb. 27, 2015. Following this transaction, the Treasure & CFO owned 1,000 shares meaning that the stake was boosted by 100% with the 500-share transaction.

Lemoine David A, who is Director at L S Starrett, bought 100 shares at $17.36 on Feb. 27, 2015. Following this transaction, the Director owned 1,200 shares meaning that the stake was boosted by 9.09% with the 100-share transaction.

The shares most recently traded at $21.62, up $4.26, or 19.7% since the insider transaction.

The average volume for L S Starrett has been 16,300 shares per day over the past 30 days. L S Starrett has a market cap of $134.9 million and is part of the industrial goods sector and industrial industry. Shares are up 8.63% year-to-date as of the close of trading on Friday.

The L.S. Starrett Company manufactures and sells industrial, professional, and consumer measuring and cutting tools and related products primarily in North America, Brazil, China, and the United Kingdom. The stock currently has a dividend yield of 1.84%. The company has a P/E ratio of 18.7. Currently, there are no analysts who rate L S Starrett a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCX - FREE

TheStreet Quant Ratings rates L S Starrett as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full L S Starrett Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Insight (NSIT) - FREE Research Report

Andrews Steven Robert, who is General Counsel and Secretary at Insight, sold 2,250 shares at $26.17 on Feb. 27, 2015. Following this transaction, the General Counsel and Secretary owned 14,086 shares meaning that the stake was reduced by 13.77% with the 2,250-share transaction.

Leighty Dana A., who is Vp, Pao at Insight, sold 3,000 shares at $26.78 on Feb. 27, 2015. Following this transaction, the Vp, Pao owned 2,728 shares meaning that the stake was reduced by 52.37% with the 3,000-share transaction.

The shares most recently traded at $27.10, up $0.32, or 1.17% since the insider transaction. Historical insider transactions for Insight go as follows:

  • 4-Week # shares sold: 26,713
  • 12-Week # shares sold: 26,713
  • 24-Week # shares sold: 26,713

The average volume for Insight has been 188,600 shares per day over the past 30 days. Insight has a market cap of $1.1 billion and is part of the technology sector and computer software & services industry. Shares are up 1.58% year-to-date as of the close of trading on Friday.

Insight Enterprises, Inc. provides information technology (IT) hardware, software, and services solutions that manages and secures IT environments for businesses and government clients. The company has a P/E ratio of 14.7. Currently, there are no analysts who rate Insight a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NSIT - FREE

TheStreet Quant Ratings rates Insight as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Insight Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Economist Perspective: Brexit Endgame in Sight?

Economist Perspective: Brexit Endgame in Sight?

Flashback Friday: Johnson & Johnson Hits Take Historic Plunge

Flashback Friday: Johnson & Johnson Hits Take Historic Plunge

Dow, S&P, Nasdaq Are All in Correction Territory Following Stock Selloff

Dow, S&P, Nasdaq Are All in Correction Territory Following Stock Selloff

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

5 Highly Anticipated Tech IPOs to Watch in 2019

5 Highly Anticipated Tech IPOs to Watch in 2019